Study the effect and mechanism of edaravone on acute ischemic cerebrovascular disease
10.3969/j.issn.1671-8348.2015.03.016
- VernacularTitle:依达拉奉对急性缺血性脑血管病的疗效研究及机制探讨
- Author:
Xianping JIANG
;
Qichun WANG
;
Dahong WU
- Publication Type:Journal Article
- Keywords:
acute disease;
brain ischemia;
nervous system disease;
edaravone;
clinical effect
- From:
Chongqing Medicine
2015;(3):334-336
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of edaravone on acute ischemic cerebrovascular disease ,and to observe its effect on serum C‐reactive protein (CRP) and matrix metalloproteinase‐9(MMP‐9) level .Methods Eighty four patients with acute ischemic cerebral vascular disease who were treated in our hospital during 2012 May to 2013 December were selected and divided in‐to observation group and control group ,with 42 cases in each group .The control group was treated with anti‐platelet ,regulating blood pressure and blood lipid ,reducing intracranial pressure ,improve microcirculation and other comprehensive treatment ;the pa‐tients in observation group were treated with increased dose of edaravone on the basis of the control group .America national institu‐tes of health stroke scale(NIHSS) and activities of daily living scale (ADL) were used to evaluate the neurological function and ac‐tivities of daily living ability of patients before and after the treatment ,the CRP and MMP‐9 level were detected before and after treatment ,and the adverse reaction during the treatment was recorded .Results After one week and two weeks after treatment , there were significant differences between treatment group and control group in the NIHSS score and ADL score (P<0 .05) ,and there were significant differences between treatment group and control group in CRP and MMP‐9 (P<0 .05) .There was no signifi‐cant difference between treatment group and control group in the reoccurrence rate of adverse reaction (7 .14% vs .4 .76% )(P>0 .05) .Conclusion Edaravone could improve the clinical treatment effect of acute ischemic cerebrovascular disease ,and reducing se‐rum CRP and MMP‐9 level mechanism pathway might be involved in the regulation of its pharmacodynamics .
